Inventor · disambiguated record
Jonathan D. Low
Also filed as: LOW JONATHAN D · LOW JONATHAN DANTE
27 granted patents·11 pending applications·259 citations·filing 2011–2025
96Inventor score
Top patents by PatentIndex Score
38 records- 0198US11993597B2Inhibitors of KRAS G12C and methods of using the sameAMGEN INC·Filed 2022·Granted May 28, 2024·8 cites·50 claims
- 0298US11766436B2KRAS G12C inhibitors and methods of using the sameAMGEN INC·Filed 2021·Granted Sep 26, 2023·11 cites·19 claims
- 0398US11306087B2Inhibitors of KRAS G12C and methods of using the sameAMGEN INC·Filed 2020·Granted Apr 19, 2022·16 cites·55 claims
- 0498US11090304B2KRAS G12C inhibitors and methods of using the sameAMGEN INC·Filed 2019·Granted Aug 17, 2021·33 cites·3 claims
- 0598US10640504B2Inhibitors of KRAS G12C and methods of using the sameAMGEN INC·Filed 2018·Granted May 5, 2020·50 cites·71 claims
- 0697US10988485B2KRAS G12C inhibitors and methods of using the sameAMGEN INC·Filed 2019·Granted Apr 27, 2021·27 cites·51 claims
- 0796US12083121B2Substituted piperazines as KRAS G12C inhibitorsAMGEN INC·Filed 2022·Granted Sep 10, 2024·7 cites·5 claims
- 0896US11285156B2Substituted piperazines as KRAS G12C inhibitorsAMGEN INC·Filed 2019·Granted Mar 29, 2022·16 cites·4 claims
- 0996US9611261B2Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of useAMGEN INC·Filed 2015·Granted Apr 4, 2017·25 cites·40 claims
- 1095US9085576B2Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of useAMGEN INC·Filed 2014·Granted Jul 21, 2015·31 cites·60 claims
- 1193US12440491B2KRAS G12C inhibitors and methods of using the sameAMGEN INC·Filed 2023·Granted Oct 14, 2025·1 cites·4 claims
- 1293US10632128B2Compounds that inhibit Mcl-1 proteinAMGEN INC·Filed 2019·Granted Apr 28, 2020·5 cites·49 claims
- 1389US12054476B2KIF18A inhibitorsAMGEN INC·Filed 2021·Granted Aug 6, 2024·1 cites·31 claims
- 1488US9593129B2Piperidinone derivatives as MDM2 inhibitors for the treatment of cancerAMGEN INC·Filed 2016·Granted Mar 14, 2017·5 cites·18 claims
- 1588US9296736B2Piperidinone derivatives as MDM2 inhibitors for the treatment of cancerAMGEN INC·Filed 2014·Granted Mar 29, 2016·7 cites·13 claims
- 1688US2025381187A1Kras g12c inhibitors and methods of using the sameAMGEN INC·Filed 2025·Application pending·0 cites
- 1787US11236069B2KIF18A inhibitorsAMGEN INC·Filed 2019·Granted Feb 1, 2022·4 cites·25 claims
- 1887US2024300892A1Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of CancerAMGEN INC·Filed 2023·Application pending·0 cites
- 1985US12509442B2KIF18A inhibitorsAMGEN INC·Filed 2024·Granted Dec 30, 2025·0 cites·32 claims
- 2084US2024287068A1Inhibitors of kras g12c and methods of using the sameAMGEN INC·Filed 2024·Application pending·0 cites
- 2181US8957083B2Spiro-amino-imidazolone and spiro-amino-dihydro-pyrimidinone compounds as beta-secretase modulators and methods of useMINATTI ANA ELENA·Filed 2011·Granted Feb 17, 2015·4 cites·19 claims
- 2280US9012446B2Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of useAMGEN INC·Filed 2013·Granted Apr 21, 2015·4 cites·20 claims
- 2380US2022169611A1Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of CancerAMGEN INC·Filed 2022·Application pending·0 cites
- 2475US12459932B2KIF18A inhibitorsAMGEN INC·Filed 2019·Granted Nov 4, 2025·1 cites·34 claims
- 2574US2021179560A1Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of CancerAMGEN INC·Filed 2020·Application pending·0 cites
- 2673US9296734B2Perfluorinated 5,6-dihydro-4H-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of useAMGEN INC·Filed 2014·Granted Mar 29, 2016·2 cites·39 claims
- 2772US11224601B1Compounds that inhibits MCL-1 proteinAMGEN INC·Filed 2020·Granted Jan 18, 2022·0 cites·15 claims
- 2869US10821115B2Compounds that inhibit Mcl-1 proteinAMGEN INC·Filed 2020·Granted Nov 3, 2020·0 cites·43 claims
- 2969US9550762B2Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of useAMGEN INC·Filed 2015·Granted Jan 24, 2017·1 cites·95 claims
- 3067US2019062276A1Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of CancerAMGEN INC·Filed 2018·Application pending·0 cites
- 3165US2014011796A1Piperidinone derivatives as mdm2 inhibitors for the treatment of cancerAMGEN INC·Filed 2013·Application pending·0 cites
- 3264US2017144971A1Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of CancerAMGEN INC·Filed 2017·Application pending·0 cites
- 3352US12473289B2Heterocyclic compounds as delta-5 desaturase inhibitors and methods of useAMGEN INC·Filed 2020·Granted Nov 18, 2025·0 cites·10 claims
- 3451US2022289724A1Kif18a inhibitorsAMGEN INC·Filed 2020·Application pending·0 cites
- 3548US11279712B2Macrocyclic compounds that inhibit MCL-1 proteinAMGEN INC·Filed 2018·Granted Mar 22, 2022·0 cites·21 claims
- 3648US10889581B2Cyclopropyl fused thiazine derivatives as beta-secretase inhibitors and methods of useAMGEN INC·Filed 2017·Granted Jan 12, 2021·0 cites·21 claims
- 3747US2015252011A1Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of useAMGEN INC·Filed 2015·Application pending·0 cites
- 3846US2017267673A1Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of useAMGEN INC·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Jonathan D. Low files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →